Proposal for MCC950 (catalog vac-32588, InvivoGen)

Overview of Therapeutic Candidate:
MCC950 is a small-molecule inhibitor originally identified as a potent and selective blocker of the NLRP3 inflammasome. Chemically, MCC950 belongs to the diarylsulfonylurea class and was discovered through phenotypic screening aimed at finding compounds that inhibit interleukin-1β (IL-1β) processing—a crucial mediator in inflammatory responses. The synthesis of MCC950 involved modification of sulfonylurea structures, evolving from earlier sulfonylurea compounds such as glyburide, to yield a molecule with enhanced specificity and potency toward NLRP3 (Coll et al., 2015, pp. 1–2). MCC950’s design capitalizes on its central sulfonylurea scaffold, which facilitates hydrogen bonding and crucial hydrophobic interactions with the target protein’s nucleotide‐binding domain. Historically, sulfonylurea derivatives have been used primarily as antidiabetic agents due to their insulin secretagogue effects; however, the subclass of diarylsulfonylureas, including MCC950, has been repurposed and optimized for anti‐inflammatory applications via selective inhibition of the NLRP3 inflammasome (Agarwal et al., 2020, pp. 3–6; Coll et al., 2015, pp. 2–4). Its chemical structure, characterized by a hexahydroindacene moiety linked to a sulfonylurea core and a furan substituent, defines its molecular identity and has provided a template for subsequent analog development. This synthetic origin underscores the potential for medicinal chemistry optimization both in terms of potency and relative pharmacokinetic properties.

Therapeutic History:
The primary use of MCC950 has been in the context of inflammatory diseases driven by aberrant activation of the NLRP3 inflammasome. Over the past decade, extensive preclinical studies have demonstrated that MCC950 is effective in reducing IL-1β and IL-18 secretion in various in vitro and animal models of autoinflammatory, metabolic, and neurodegenerative conditions (Coll et al., 2015, pp. 8–9; Vande Walle et al., 2019, pp. 1–2). Its potent inhibition of NLRP3 activation has been validated in disease models such as experimental autoimmune encephalomyelitis for multiple sclerosis and murine models of cryopyrin-associated periodic syndromes (CAPS) (Baldwin et al., 2016, pp. 8–11; Perera et al., 2018, pp. 1–2). Although MCC950 has not been clinically tested specifically for dry age‐related macular degeneration (AMD), its robust efficacy in mitigating inflammation in non‐ocular models and its proven ability to penetrate ocular tissues in nonhuman primate models of ocular inflammation suggest translational potential for retinal diseases. The anti‐inflammatory profile of MCC950, particularly in terms of inhibiting the caspase-1 activation and IL‐1β processing, has led to clinical interest in applications that extend beyond its initial target indications. Notably, small-molecule inhibitors of NLRP3 like MCC950 have been highlighted for their oral bioavailability and lack of interference with other inflammasome pathways, which classic biologics such as IL-1β neutralizing antibodies do not offer (Coll et al., 2015, pp. 22–26; Vande Walle et al., 2019, pp. 23–24). While previous uses of MCC950 or similar diarylsulfonylurea compounds have been focused on systemic inflammatory conditions, the mechanistic insights regarding NLRP3 involvement in retinal pigment epithelium (RPE) dysfunction and AMD pathogenesis are emerging, and preclinical studies have increasingly supported the repurposing of inflammasome inhibitors as therapeutic agents for dry AMD (Kaur et al., 2025, pp. 14–16; Xu et al., 2023, pp. 18–29).

Mechanism of Action:
At the molecular level, MCC950 exerts its therapeutic effect by targeting the NACHT domain of the NLRP3 inflammasome—a critical region responsible for ATP hydrolysis and subsequent inflammasome oligomerization. MCC950 binds directly to the ATP-binding cassette within the NACHT domain, particularly interacting with motifs such as the Walker B motif, thereby preventing the conformational change necessary for NLRP3 activation (Baldwin et al., 2016, pp. 8–11; Zhan et al., 2023, pp. 7–8). This binding stabilizes NLRP3 in an inactive “closed” conformation, ultimately blocking the oligomerization of the adaptor protein ASC and inhibiting caspase-1 activation. Because caspase-1 activation is essential for the cleavage of pro-IL-1β into its mature form, MCC950 indirectly prevents the release of IL-1β and IL-18, key mediators of inflammation (El-Sayed et al., 2022, pp. 3–4; Coll et al., 2015, pp. 4–6). Moreover, MCC950’s mechanism of action is highly selective; it does not interfere with other inflammasomes such as NLRC4 or AIM2, ensuring that the normal host defense mechanisms are preserved (Vande Walle et al., 2019, pp. 2–3; Perera et al., 2018, pp. 2–4). Recent structural studies have further revealed that MCC950’s interactions involve multiple hydrophobic contacts and hydrogen bonds within the NACHT domain, which contribute to its high affinity and selectivity (Kaur et al., 2025, pp. 6–8; Keuler et al., 2022, pp. 4–5). The detailed molecular insights imply that by preventing the ATPase activity of NLRP3, MCC950 halts the downstream inflammatory cascade that would otherwise aggravate tissue damage in chronic inflammatory diseases. Although some reports note that MCC950 may have limited effects on specific gain-of-function NLRP3 mutants (as seen in certain CAPS cases), its efficacy on wild-type NLRP3—relevant to sterile inflammatory conditions such as those observed in dry AMD—remains robust (Vande Walle et al., 2019, pp. 15–17; Wu et al., 2020, pp. 1–3).

Expected Effect:
In the context of dry age-related macular degeneration, the hypothesis is that MCC950 will alleviate chronic inflammation in the retinal pigment epithelium (RPE) by inhibiting NLRP3-dependent IL-1β secretion. NLRP3 activation in RPE cells is known to impair the normal phagocytic function of these cells and contribute to a pro-inflammatory microenvironment that exacerbates the accumulation of photoreceptor debris—a critical factor in the pathogenesis of dry AMD (Kaur et al., 2025, pp. 40–46). By blocking the ATPase activity of NLRP3, MCC950 is expected to restore the expression and function of phagocytic receptors that become suppressed under chronic inflammatory conditions. The effect is hypothesized to manifest as an indirect enhancement in the clearance of photoreceptor outer segments, thereby slowing or even reversing the accumulation of cellular debris that contributes to RPE dysfunction. Additionally, preclinical models have demonstrated that restoration of phagocytic gene expression in RPE is achievable through specific inhibition of inflammatory checkpoints, which in turn may lead to a reduction in secondary degenerative changes such as geographic atrophy (Harrison et al., 2020, pp. 1–2; Perera et al., 2018, pp. 9–10). Studies in other inflammatory models have shown that oral administration of MCC950 significantly reduces localized inflammation without broadly immunosuppressing the host, thereby supporting its use as a targeted therapeutic for ocular inflammatory conditions (Coll et al., 2015, pp. 6–8; Xu et al., 2023, pp. 6–7). It is important to note that RPE cells express NLRP3 and its downstream effectors, implying that direct inhibition could modulate critical signaling pathways involved in both inflammasome assembly and phagocytosis (Baldwin et al., 2016, pp. 8–11; Wu et al., 2020, pp. 6–7). The expected outcome in the proposed assay is a reduction in IL-1β levels, an improvement in RPE receptor expression profiles, and an enhanced clearance of debris, which collectively may contribute to a stabilization or improvement in retinal function in a dry AMD setting.

Overall Evaluation:
From the gathered literature and mechanistic insights, MCC950 appears to be a highly promising candidate for repurposing in the treatment of dry age-related macular degeneration. One of the primary strengths of MCC950 is its well-defined mechanism of action, which involves direct inhibition of the NLRP3 inflammasome by binding to the NACHT domain and blocking ATPase activity. This targeted inhibition leads to a significant reduction in caspase-1 activation and IL-1β/IL-18 cytokine maturation, processes that are key drivers of chronic inflammation and associated tissue damage (Coll et al., 2015, pp. 8–9; Vande Walle et al., 2019, pp. 23–24). The high specificity of MCC950 ensures minimal off-target effects compared to broader anti-inflammatory agents, which is crucial for maintaining normal immune responses in the retina and systemically (Baldwin et al., 2016, pp. 8–11; Wu et al., 2020, pp. 1–3).

Another significant strength is the extensive preclinical evidence supporting its anti-inflammatory efficacy across multiple disease models—including those that mimic inflammatory ocular conditions. Although dry AMD has unique pathophysiological features related to RPE dysfunction and extracellular debris accumulation, the underlying chronic inflammatory process driven by NLRP3 activation is shared across several inflammatory disorders. This translational overlap suggests that MCC950’s ability to restore RPE phagocytosis and reduce inflammatory cytokine production could translate effectively into therapeutic outcomes for dry AMD (Kaur et al., 2025, pp. 14–16; Xu et al., 2023, pp. 18–29).

Furthermore, MCC950 has demonstrated desirable pharmacokinetic properties, including oral bioavailability and tissue penetration in nonhuman primate ocular inflammation models. This is particularly important for a chronic condition such as dry AMD, where long-term oral administration is preferable over invasive treatments. The use of a small-molecule inhibitor such as MCC950 offers practical advantages over biologics, which are often limited by cost, administration route, and immunogenicity (Coll et al., 2015, pp. 1–2; Vande Walle et al., 2019, pp. 1–2).

Nevertheless, there are important considerations that need to be addressed. One potential weakness is the observation that MCC950 exhibits reduced efficacy against certain gain-of-function NLRP3 mutants, as highlighted in some studies. However, in the case of dry AMD—which is generally associated with wild-type NLRP3 activation rather than mutant forms—this limitation may be less critical (Vande Walle et al., 2019, pp. 15–17; Wu et al., 2020, pp. 1–3). Additionally, there has been concern regarding hepatotoxicity in some clinical contexts, as seen in earlier phase trials for rheumatoid arthritis, raising safety considerations for chronic systemic use. Nonetheless, given the localized nature of retinal pathology, careful dosing or targeted delivery strategies (e.g., via ocular formulations) may mitigate potential systemic side effects while ensuring sufficient drug levels at the site of pathology (Xu et al., 2023, pp. 18–29; Perera et al., 2018, pp. 9–10).

Another area requiring further validation is the link between NLRP3-mediated inflammation and the suppression of phagocytic receptors in RPE cells. While emerging preclinical studies indicate that NLRP3 activation impairs RPE function—likely via IL-1β–driven processes—the precise molecular relationship and downstream signaling events remain under active investigation. It will be crucial to verify whether MCC950 can restore normal phagocytosis and clearance of photoreceptor debris in robust preclinical AMD models. The proposed mechanism, whereby inhibition of IL-1β alleviates secondary suppression of phagocytic receptors, is biologically plausible given the established literature on inflammasome-driven cytokine cascades and RPE dysfunction (Kaur et al., 2025, pp. 40–46; Coll et al., 2015, pp. 22–26).

Moreover, the direct inhibition of NLRP3 by MCC950 has been shown to modulate systemic inflammatory responses without interfering with upstream ion fluxes such as potassium or chloride efflux, which are critical for normal cellular homeostasis. With its mechanism focusing on directly stabilizing NLRP3 in an inactive conformation, MCC950 presents minimal risk to physiological processes that rely on these ionic changes (Wu et al., 2020, pp. 3–4; Zhan et al., 2023, pp. 7–8). This implies that its therapeutic window in chronic conditions like dry AMD might be favorable if dosing strategies are optimized for retinal delivery while minimizing systemic exposure.

In terms of translational feasibility, the candidate’s small-molecule nature enhances manufacturability and scalability in a clinical development setting. Its defined chemical structure, amenability to oral administration, and documented efficacy in other inflammatory disease models together provide a compelling rationale for advancing further preclinical studies in dry AMD. The emphasis on targeting a specific inflammasome checkpoint represents a novel mechanistic approach compared to existing broad-spectrum anti-inflammatory agents, which often come with considerable side effects and suboptimal efficacy in degenerative retinal diseases (Coll et al., 2015, pp. 4–6; Xu et al., 2023, pp. 6–7).

Overall, the evidence supports that MCC950 is a promising therapeutic candidate for dry age-related macular degeneration. Its natural origins from repurposed sulfonylurea scaffolds, extensive preclinical validation in non-ocular inflammatory models, and detailed molecular mechanism targeting the NLRP3 inflammasome constitute significant strengths. However, further studies in relevant AMD models are essential to confirm its ability to restore RPE phagocytosis and improve photoreceptor debris clearance while carefully monitoring for potential systemic side effects, particularly hepatotoxicity. In summary, while challenges remain regarding safety optimization and validation of efficacy in ocular models, MCC950 presents a mechanistically specific and translationally feasible approach to treating dry AMD by modulating inflammasome-driven inflammation in the retinal pigment epithelium (Coll et al., 2015, pp. 6–8; Vande Walle et al., 2019, pp. 23–24; Kaur et al., 2025, pp. 17–19).

References
Agarwal, S., Pethani, J. P., Shah, H. A., Vyas, V., Sasane, S., Bhavsar, H., Bandyopadhyay, D., Giri, P., Viswanathan, K., Jain, M. R., & Sharma, R. (2020). Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor. Bioorganic & Medicinal Chemistry Letters, 30, 127571. https://doi.org/10.1016/j.bmcl.2020.127571

Baldwin, A. G., Brough, D., & Freeman, S. (2016). Inhibiting the inflammasome: A chemical perspective. Journal of Medicinal Chemistry, 59(5), 1691–1710. https://doi.org/10.1021/acs.jmedchem.5b01091

Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., Croker, D. E., Butler, M. S., Haneklaus, M., Sutton, C. E., Núñez, G., Latz, E., Kastner, D. L., Mills, K. H. G., Masters, S. L., ... O’Neill, L. A. J. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21, 248–255. https://doi.org/10.1038/nm.3806

El-Sayed, S., Freeman, S., & Bryce, R. A. (2022). A selective review and virtual screening analysis of natural product inhibitors of the NLRP3 inflammasome. Molecules, 27, 6213. https://doi.org/10.3390/molecules27196213

Harrison, D., Boutard, N., Brzozka, K., Bugaj, M., Chmielewski, S., Cierpich, A., Doedens, J. R., Fabritius, C.-H. R. Y., Gabel, C. A., Galezowski, M., Kowalczyk, P., Levenets, O., Mroczkowska, M., Palica, K., Porter, R. A., Schultz, D., Sowinska, M., Topolnicki, G., Urbanski, P., ... Watt, A. P. (2020). Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors. Bioorganic & Medicinal Chemistry Letters, 30, 127560. https://doi.org/10.1016/j.bmcl.2020.127560

Kaur, B., Biby, S., Namme, J. N., More, S., Xu, Y., & Zhang, S. (2025). Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors. Advances in Pharmacology, 102, 103–157. https://doi.org/10.1016/bs.apha.2024.10.004

Keuler, T., Ferber, D., Marleaux, M., Geyer, M., & Gütschow, M. (2022). Structure–stability relationship of NLRP3 inflammasome-inhibiting sulfonylureas. ACS Omega, 7, 8158–8162. https://doi.org/10.1021/acsomega.2c00125

Perera, A. P., Fernando, R., Shinde, T., Gundamaraju, R., Southam, B., Sohal, S. S., Robertson, A. A. B., Schroder, K., Kunde, D., & Eri, R. (2018). MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Scientific Reports. https://doi.org/10.1038/s41598-018-26775-w

Vande Walle, L., Stowe, I. B., Šácha, P., Lee, B. L., Demon, D., Fossoul, A., Van Hauwermeiren, F., Saavedra, P. H. V., Šimon, P., Šubrt, V., Kostka, L., Stivala, C. E., Pham, V. C., Staben, S. T., Yamazoe, S., Konvalinka, J., Kayagaki, N., & Lamkanfi, M. (2019). MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. PLOS Biology, 17, e3000354. https://doi.org/10.1371/journal.pbio.3000354

Wu, D.-b., Chen, Y.-f., Sun, Y., Gao, Q., Li, H., Yang, Z., Wang, Y., Jiang, X., & Yu, B. (2020). Target of MCC950 in inhibition of NLRP3 inflammasome activation: A literature review. Inflammation, 43, 17–23. https://doi.org/10.1007/s10753-019-01098-8

Xu, Y., Biby, S., Kaur, B., & Zhang, S. (2023). A patent review of NLRP3 inhibitors to treat autoimmune diseases. Expert Opinion on Therapeutic Patents, 33, 455–470. https://doi.org/10.1080/13543776.2023.2239502

Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z. (2023). The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.1109938
